Expert: Biomarker-driven care set to shape future of prostate cancer management

In a recent interview conducted at the 2025 LUGPA Annual Meeting, Jason M. Hafron, MD, CMO, touched on the growing shift toward biomarker-driven therapy in advanced prostate cancer. Hafron is the chief medical officer at the Michigan Institute of Urology.

Hafron noted that nearly 40% of recent drug approvals are tied to biomarker-based trials in recent years, emphasizing the importance of both somatic and germline testing to ensure patients receive the most targeted and effective treatments.

Looking ahead to 2026, he notes excitement around the upcoming readout of the international PROTEUS trial (NCT03767244), which is evaluating disease-intensification strategies with apalutamide (Erleada). According to Hafron, this trial could lead to significant guideline changes depending on the results.